|
POTENTIATION OF ORTHOSTATIC HYPOTENSION
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS LIPID-LOWERING DOSES OF NIACIN ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS LIPID-LOWERING DOSES OF NIACIN ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS LIPID-LOWERING DOSES OF NIACIN ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS LIPID-LOWERING DOSES OF NIACIN ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|